Goldman Sachs Lowers First Solar Price Target Amid Uncertainties

Published 1 days agoFSLR

Goldman Sachs Lowers First Solar Price Target Amid Uncertainties

Goldman Sachs has recently adjusted its price target for First Solar, reflecting a more cautious stance amidst ongoing global uncertainties. The bank's analyst, Brian Lee, maintained a "Buy" rating for First Solar but reduced the price target from $235 to $204, signaling potential concerns affecting the solar panel manufacturer.

According to investing.com, this decision came as of April 30, 2025, when Goldman Sachs acknowledged the company's challenges in navigating the shifting landscape of global tariffs. On May 30, Reuters reported that the price target remained at $204, reinforcing the bank's consistent evaluation over the month.

First Solar has been facing an unpredictable market environment, where external factors such as tariffs are creating headwinds. While the company continues to hold investor confidence with a "Buy" rating, the lowered price target suggests a degree of prudence in the face of these broader economic influences.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Citigroup Appoints Wenjie Zhang as China Country Head

Citigroup Appoints Wenjie Zhang as China Country Head

Citigroup has announced the appointment of Wenjie Zhang as its new China country officer and head of banking, effective July 2025. Zhang will be based in Shanghai and will have a direct reporting line to Marc Luet, Citi's Head of Japan, Asia North, and Australia and Banking, according to Reuters. Zhang steps into the role following the departure of his predecessor, Luke Lu, who left Citigroup in November 2024 for personal reasons. In addition to his new position, Zhang will also hold the titles of president and executive director of Citibank China, subject to regulatory approval. Zhang brings with him 30 years of substantial experience in corporate and institutional banking, having previously served as the president of China and Shanghai branch manager for Bank of America China. His extensive career also includes senior roles at HSBC China, JPMorgan, Citi, and Credit Agricole CIB. Zhang's responsibilities will encompass leading Citi’s operations in mainland China, bolstering regulatory relationships, and enhancing risk controls. This appointment comes as Citi continues to restructure its global operations, with efforts to internalize staffing to improve risk management and data governance. Additionally, Citi is planning to establish a securities unit in China, expanding its footprint in the region.

HSBC Commits $4 Billion to Boost Private Credit Funds

HSBC Commits $4 Billion to Boost Private Credit Funds

34 minutes agoHSBC

HSBC has announced a substantial $4 billion investment into its private credit funds, a move aimed at strengthening its role in the fast-evolving $2 trillion private credit market. According to Reuters, the funds will be channeled through HSBC Asset Management's alternative credit funds with the aim of attracting external capital and reaching a $50 billion credit fund milestone within five years. This strategic endeavor is part of CEO Georges Elhedery's broader plan to diversify HSBC's revenue streams as the bank faces challenges in maintaining profits from traditional lending. This pivot is seen as a response to the rapid growth of the private credit market, which industry insiders expect to swell to $3 trillion by 2028, notes a report by Brecorder. HSBC Asset Management has been active in the private credit space since 2018, successfully executing $7 billion across 150 deals. With this new infusion, HSBC targets global investments with a priority on direct lending in the UK and Asia. This move aligns with a wider industry trend where financial institutions are increasingly investing in private credit to bolster earnings and add diversity to their revenue bases, as highlighted by Reuters.

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

49 minutes agoSNY

Sanofi has recently announced its plan to acquire Blueprint Medicines for up to $9.5 billion, combining cash and stock elements. This strategic move is designed to boost Sanofi's portfolio in the immunology sector, allowing the pharmaceutical giant to integrate Blueprint Medicines' innovative therapies into its existing suite of offerings. The acquisition highlights Sanofi's strategic goal of strengthening its position in immunology, particularly through the incorporation of Blueprint Medicines' promising pipeline. This pipeline includes treatments for various immunological conditions, which aptly complements Sanofi's current portfolio. The deal's completion is contingent on customary regulatory approvals and is anticipated to close in the second half of 2025. Sanofi has expressed expectations that this transaction will be accretive to its earnings per share in the first year following the deal's closure. Sanofi's CEO underlined the alignment of Blueprint Medicines' assets with the company's focus on immunology, emphasizing the acquisition’s potential to address unmet medical needs. Notably, after the announcement, there was a slight dip in Sanofi's share price, as reported by Reuters, while Blueprint Medicines' shares experienced a modest uptick. This acquisition reaffirms Sanofi's dedication to enhancing its capabilities in the immunology field and bringing forward new treatments for patients globally.

Plus Therapeutics Posts Wider Than Expected Losses Despite Revenue Gains in Q1 2025

Plus Therapeutics Posts Wider Than Expected Losses Despite Revenue Gains in Q1 2025

1 hours agoPSTV

Plus Therapeutics, Inc., trading under NASDAQ as PSTV, recently disclosed its financial results for the first quarter of 2025, revealing a GAAP EPS of -$1.19. This figure fell short of analyst expectations by $0.97, highlighting the firm’s struggle to meet financial forecasts. Despite this, the company managed to generate $1.06 million in revenue for the quarter. The company reported a net loss of $3.26 million, or $0.75 per share, which marks an improvement from last year's net loss of $4.81 million, or $2.07 per share. Operating losses also decreased from $4.7 million last year to $3.3 million this quarter. In terms of grants, Plus Therapeutics recognized $1.68 million in grant revenue, notably higher than the $0.51 million received in the same period of the previous year. However, their cash and investments balance saw a decline to $4.8 million as of March 31, 2025, down from $8.6 million at the end of 2024. In terms of clinical developments, Plus Therapeutics received FDA approval to start enrolling patients for their ReSPECT-LM trial targeting leptomeningeal metastases, which is set to begin in early 2025. This development is part of the company's broader strategy to advance its lineup of targeted radiotherapeutics for central nervous system cancers. The ongoing strategic efforts reflect Plus Therapeutics' commitment to overcoming financial and operational challenges while focusing on expanding its innovative therapeutic pipeline.